References

Ackland, J.R., D.A. Worswick, and B.P. Marmion. 1994. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Medical Journal of Australia 160(11):704-708.

Barrera Oro, J.G., J.I. Maiztegui, and C.J. Peters. 1988. Safety and immunogenicity of a live attenuated Junín virus vaccine (Candid-1) in human volunteers. Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region, Mar del Plata, Argentina.

Barry, M.A. 2005. Report of Pneumonic Tularemia in Three Boston University Researchers: November 2004–March 2005. Boston Public Health Commission.

Birt, C., and G. Lamb. 1899. Mediterranean or Malta fever. Lancet 154(3967):701-706.

Boudreau, E. 2010. Special Immunizations Program, USAMRIID. Presentation at the First Meeting of the Committee on Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents, Mar. 4, 2010, Washington, DC.

Casadevall, A., and L.-A. Pirofski. 1999. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infection and Immunity 67(8):3703-3713.

CBDP (Chemical and Biological Defense Program). 2010. Annual Report to Congress. U.S. Department of Defense Chemical and Biological Defense Program [online]. Available: http://www.acq.osd.mil/cp/cbdreports/cbdpreporttocongress2010.pdf [accessed Mar. 8, 2011].

CDC (Centers for Disease Control and Prevention). 2000. Laboratory-acquired human glanders—Maryland, May 2000. Morbidity and Mortality Weekly Report 49(24):532-535.

CDC. 2002a. Public Health Dispatch: Update: Cutaneous anthrax in a laboratory worker—Texas, 2002. Morbidity and Mortality Weekly Report 51(22):482.

CDC. 2002b. Suspected cutaneous anthrax in a laboratory worker—Texas, 2002. Morbidity and Mortality Weekly Report 51(13):279-281.

CDC. 2008a. Laboratory-acquired brucellosis—Indiana and Minnesota, 2006. Morbidity and Mortality Weekly Report 57(02):39-42.

CDC. 2008b. Laboratory-acquired vaccinia exposures and infections—United States, 2005-2007. Morbidity and Mortality Weekly Report 57(15):401-404.

CDC. 2008c. Update: Potential exposures to attenuated vaccine strain Brucella abortus RB51 during a laboratory proficiency test—United States and Canada, 2007. Morbidity and Mortality Weekly Report 57(02):36-39.

CDC 2009. Laboratory-acquired vaccinia virus infection—Virginia, 2008. Morbidity and Mortality Weekly Report 58(29):797-800.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 139
References Ackland, J.R., D.A. Worswick, and B.P. Marmion. 1994. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Medical Journal of Australia 160(11):704-708. Barrera Oro, J.G., J.I. Maiztegui, and C.J. Peters. 1988. Safety and immunogenicity of a live attenu - ated Junín virus vaccine (Candid-1) in human volunteers. Second International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region, Mar del Plata, Argentina. Barry, M.A. 2005. Report of Pneumonic Tularemia in Three Boston University Researchers: Novem- ber 2004–March 2005. Boston Public Health Commission. Birt, C., and G. Lamb. 1899. Mediterranean or Malta fever. Lancet 154(3967):701-706. Boudreau, E. 2010. Special Immunizations Program, USAMRIID. Presentation at the First Meeting of the Committee on Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents, Mar. 4, 2010, Washington, DC. Casadevall, A., and L.-A. Pirofski. 1999. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infection and Immunity 67(8):3703-3713. CBDP (Chemical and Biological Defense Program). 2010. Annual Report to Congress. U.S. Depart - ment of Defense Chemical and Biological Defense Program [online]. Available: http://www. acq.osd.mil/cp/cbdreports/cbdpreporttocongress2010.pdf [accessed Mar. 8, 2011]. CDC (Centers for Disease Control and Prevention). 2000. Laboratory-acquired human glanders— Maryland, May 2000. Morbidity and Mortality Weekly Report 49(24):532-535. CDC. 2002a. Public Health Dispatch: Update: Cutaneous anthrax in a laboratory worker—Texas, 2002. Morbidity and Mortality Weekly Report 51(22):482. CDC. 2002b. Suspected cutaneous anthrax in a laboratory worker—Texas, 2002. Morbidity and Mortality Weekly Report 51(13):279-281. CDC. 2008a. Laboratory-acquired brucellosis—Indiana and Minnesota, 2006. Morbidity and Mor- tality Weekly Report 57(02):39-42. CDC. 2008b. Laboratory-acquired vaccinia exposures and infections—United States, 2005-2007. Morbidity and Mortality Weekly Report 57(15):401-404. CDC. 2008c. Update: Potential exposures to attenuated vaccine strain Brucella abortus RB51 dur- ing a laboratory proficiency test—United States and Canada, 2007. Morbidity and Mortality Weekly Report 57(02):36-39. CDC 2009. Laboratory-acquired vaccinia virus infection—Virginia, 2008. Morbidity and Mortality Weekly Report 58(29):797-800. 139

OCR for page 139
140 PROTECTING THE FRONTLINE IN BIODEFENSE RESEARCH CDC. 2011a. CDC Drug Service [online]. Available: http://www.cdc.gov/laboratory/drugservice/ index.html [accessed Apr. 22, 2011]. CDC. 2011b. Fatal laboratory-acquired infection with an attenuated Yersinia pestis strain—Chicago, Illinois, 2009. Morbidity and Mortality Weekly Report 60(07):201-205. CDC/APHIS (Centers for Disease Control and Prevention and Animal and Plant Health Inspection Service). 2008. Select Agents and Toxins: Theft, Loss and Release Information Document. 7 CFR Part 331.19, 9 CFR Part 121.19, 42 CFR Part 73.19. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Division of Select Agents and Toxins, Atlanta, GA, and U.S. Department of Agriculture, Animal and Plant Health Inspection Service, Agriculture Select Agent Program, Riverdale, MD. Jan. 18, 2008 [online]. Available: http://www.selectagents.gov/resources/CDC-APHIS_Theft_Loss_Release_Information_ Document.pdf [accessed Mar. 8, 2011]. CDC/NIH (Centers for Disease Control and Prevention and National Institutes of Health). 2009. Biosafety in Microbiological and Biomedical Laboratories, 5th Ed., L.C. Chosewood, and D.E. Wilson, eds. HHS Publication No. (CDC) 21-1112. Washington, DC: U.S. Government Printing Office [online]. Available: http://www.cdc.gov/biosafety/publications/bmbl5/BMBL. pdf [accessed Mar. 8, 2011]. Christova, I. 2009. Bulgarian vaccine against CCHFV. Presentation at Arbo-Zoonet Symposium: Interventions against WNV, RVFV and CCHFV: Where are we? Nov. 19-20, 2009, Istambul, Turkey [online]. Available: http://www.arbo-zoo.net/_data/1-Iva_Christova_istanbul09.pdf [accessed Mar. 11, 2011]. Covert, N.M. 2000. Cutting Edge: A History of Fort Detrick, Maryland, 4th Ed. Fort Detrick Public Affairs Office [online]. Available: http://www.detrick.army.mil/cutting_edge/index. cfm [accessed Mar. 8, 2011]. Crumrine, M. 2010. Special Immunizations Program: NIAID perspective. Presentation at the First Meeting of the Committee on Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents, Mar. 4, 2010, Washington, DC. DOD (U.S. Department of Defense). 2001. Report on Biological Warfare Defense Vaccine Research and Development Programs. U.S. Department of Defense, Washington DC. July 2001 [online]. Available: http://www.defense.gov/pubs/reportonbiologicalwarfaredefensevaccineRDPrgras- July2001.pdf [accessed Mar. 10, 2011]. DOD. 2008. Roles and Responsibilities Associated with the Chemical and Biological Defense (CBD) Program (CBDP). DOD Directive No. 5160.05E, Oct. 9 2008 [online]. Available: http://www. dtic.mil/whs/directives/corres/pdf/516005p.pdf [accessed Mar. 8, 2011]. DOD. 2009. Protocol for Participation in the Special Immunization Program, FY05-15, Amendment No. 4. U.S. Department of Defense, Office of the Human Use Committee. HUC Submission Dec. 10, 2009. DOD. 2010. Quadrennial Defense Reviews. U.S. Department of Defense [online]. Available: http:// www.defense.gov/qdr/ [accessed Mar. 8, 2011]. Drew, S.W. 2007. Platforms for vaccine manufacturing. Pp. 37-54 in WTEC Panel Report on Inter- national Assessment of Research and Development in Rapid Vaccine Manufacturing. World Technology Evaluation Center, Inc., Baltimore, MD [online]. Available: http://www.wtec.org/ vaccmfg/RapidVaccMfg-finalreport.pdf [accessed Mar. 8, 2011]. DVC LLC (DynPort Vaccine Company LLC). 2011. DynPort Vaccine Company LLC: Case Studies [online]. Available: http://www.csc.com/dvc [accessed Mar. 8, 2011]. Eitzen, E. 2004. Special Immunization Program (SIP) Subgroup—Weapons of Mass Destruction Medical Countermeasures (WMDMCS): Final Policy Recommendations to U.S. Homeland Security Council Policy Coordinating Committee, December 2004.

OCR for page 139
141 REFERENCES Eitzen, E. 2010. Special Immunization Program (SIP) Subgroup, Weapons of Mass Destruction Medical Countermeasures (WMDMCS): Decision Brief to U.S. Homeland Security Council PCC, Dec. 16, 2004. Presentation at the First Meeting of the Committee on Special Immuniza - tions Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents, Mar. 4, 2010, Washington DC. EMA (European Medicines Agency). 2005. Guideline on Procedures for the Granting of a Market - ing Authorisation Under Exceptional Circumstances, Pursuant to Article 14(8) of Regulation (EC) No. 726/2004. EMEA/357981/2005. Committee for Medicinal Products for Human Use (CHMP). Dec. 15, 2005 [online]. Available: http://www.ema.europa.eu/docs/en_GB/ document_library/Regulatory_and_procedural_guideline/2009/10/WC500004883.pdf [ac - cessed Nov. 2, 2010]. Enserink, M. 2009. Mystery: Did experimental vaccine save Ebola accident victim’s life? Science Insider. April 7, 2009 [online]. Available: http://news.sciencemag.org/scienceinsider/2009/04/ did-experimenta.html?sms_ss=email&at_xt=4d9619df9577ec5c%2C0. Fatz, R.J. 2003. Special Immunization Program. Memorandum to Directors of the Army Staff, from Raymond J. Fatz, Deputy Assistant Secretary of the Army (Environment, Safety and Occupa - tional Health), U.S. Department of the Army, Washington, DC. May 27, 2003. FDA (U.S. Food and Drug Administration). 2004. Public Workshop on Animal Models and Correlates of Protection for Plague Vaccines, Oc. 13, 2004, Gaithersburg, MD. U.S. Depart - ment of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research [online]. Available: http://www.fda.gov/downloads/BiologicsBlood Vaccines/NewsEvents/WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054438. pdf [accessed Dec. 13, 2010]. FDA. 2007a. Anthrax Vaccines: Bridging Correlates of Protection in Animals to Immuno- genicity in Humans: Workshop, Nov. 8, 2007, Gaithersburg, MD. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Eval - uation and Research [online]. Available: http://www.fda.gov/downloads/BiologicsBlood Vaccines/NewsEvents/WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054424. pdf [accessed Dec. 13, 2010]. FDA. 2007b. Emergency Use Authorization of Medical Products Guidance—Emergency Use Authorization of Medical Products. U.S. Department of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Counterterrorism Policy and Planning, Rockville, MD. July 2007 [online]. Available: http://www.fda.gov/oc/guidance/ emergencyuse.html [accessed July 14, 2010]. FDA. 2008. Guidance for Industry: Tropical Disease Priority Review Vouchers. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). October 2008 [online]. Available: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM080599.pdf [accessed July 14, 2010]. FDA. 2009a. Guidance for Industry: Animal Models—Essential Elements to Address Efficacy Under the Animal Rule. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Bio - logics Evaluation and Research (CBER). January 2009 [online]. Available: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078923.pdf [accessed July 14, 2010]. FDA. 2009b. Public Meeting on Animal Models—Essential Elements to Address Efficacy Un - der the Animal Rule; and Reopening of Comment Period. Docket No. FDA-2009-D-000, Nov. 5, 2010 [online]. Available: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ WorkshopsMeetingsConferences/ucm225074.htm [accessed Dec. 13, 2010].

OCR for page 139
142 PROTECTING THE FRONTLINE IN BIODEFENSE RESEARCH FDA. 2010a. Emergency Use Authorization. U.S. Food and Drug Administration [online]. Available: http://www.fda.gov/EmergencyPreparedness/Counterterrorism/ucm182568.htm [accessed July 14, 2010]. FDA. 2010b. Import and Export Guidance Documents. Regulatory Information. U.S. Food and Drug Administration [online]. Available: http://www.fda.gov/RegulatoryInformation/Guid - ances/ucm122048.htm [accessed Mar. 14, 2011]. FDA. 2010c. Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post- exposure Prophylaxis Indication Using the Animal Rule, Briefing Document for the Vaccines and Related Biological Products Advisory Committee Meeting, Nov. 16, 2010 [online]. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisory Committee/UCM232400.pdf [accessed Dec. 13, 2010]. FDA. 2010d. Transcript of the November 15, 2010 Meeting of the Science Board to the Food and Drug Administration [online]. Available: http://www.fda.gov/downloads/Advisory- Committees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/ UCM236313.pdf [accessed Dec. 13, 2010]. Fischer, M., A. Griggs, and J.E. Staples. 2009. Tick-Borne Encephalitis (TBE). Chapter 5 in CDC Information for International Travel 2010 (The Yellow Book). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Atlanta, GA [online]. Available: http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/tick-borne- encephalitis.aspx [accessed Mar. 11, 2011]. Franco, C., and T.K. Sell. 2010. Federal agency biodefense funding, FY2010-FY2011. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 8(2):129-149. Fuller, C.L., K.C. Brittingham, M.W. Porter, M.J. Hepburn, P.L. Petitt, P.R. Pittman, and S. Bavari. 2007. Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination. Molecular Immunology 44(12):3173-3184. GAO (U. S. General Accounting Office). 1991. Biological Warfare: Role of Salk Institute in Army’s Research Program. GAO/NSIAD-92-33. Washington, DC: U.S. General Accounting Office. December 1991 [online]. Available: http://archive.gao.gov/t2pbat7/145851.pdf [accessed Mar. 8, 2011]. GAO (U.S. Government Accountability Office). 2007. High-Containment Biosafety Laboratories: Preliminary Observations on the Oversight of the Proliferation of BSL-3 and BSL-4 Laborato - ries in the United States. Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives. GAO-08-108T. Washington, DC: U.S. Government Accountability Office [online]. Available: http://www.absa.org/leg/07 12GAOHighContainmentLabsReport.pdf [accessed Mar. 8, 2011]. GAO. 2009a. High-Containment Laboratories: National Strategy for Oversight Is Needed. GAO- 09-574. Washington, DC: U.S. Government Accountability Office. September 2009 [online]. Available: http://www.gao.gov/new.items/d09574.pdf [accessed Mar. 8, 2011]. GAO. 2009b. High-Containment Laboratories: National Strategy for Oversight is Needed. Tes - timony Before the Subcommittee on Terrorism and Homeland Security, Committee on the Judiciary, Senate. GAO-09-1045T. Washington, DC: U.S. Government Accountability Office [online]. Available: http://www.gao.gov/new.items/d091045t.pdf [accessed Mar. 8, 2011]. Gidding, H., C. Wallace, G.L. Lawrence, and P.B. McIntyre. 2009. Australia’s national Q fever vaccination program. Vaccine 27:2037-2041. Harding, A.L., and K.B. Byers. 2006. Epidemiology of laboratory-associated infections. Pp. 53-80 in Biological Safety Principles and Practices, 4th Ed., D.O. Fleming and D.L. Hunt, eds. Washington, DC: ASM Press.

OCR for page 139
143 REFERENCES Henchal, E.A. 2003. Changes in the Special Immunizations Program at the U.S. Army Medical Research Institute of Infectious Diseases. Memorandum for Directors of All Agencies Whose Employees Are Participants in the Special Immunizations Program at the U.S. Army Medical Research Institute of Infectious Diseases. MCMR-UIM-R. Aug. 14, 2003. HHS (U.S. Department of Health and Human Services). 2007. Public Health Emergency Medical Countermeasure Implementation Plan for Chemical, Biological and Nuclear Threats. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Prepared - ness and Response, Office of Public Health Emergency Medical Countermeasures. April 2007 [online]. Available: http://www.pswrce.uci.edu/pdf/phemce_implplan_041607final.pdf [accessed Mar. 8, 2011]. HHS. 2009a. Advanced Development of Recombinant Influenza Vaccine Products and Manu - facturing Capabilities for Pandemic Preparedness. Request for Proposal, Solicitation No. HHS-BARDA-09-32. U.S. Department of Health and Human Services. FedBiz Opps [online]. Available: https://www.fbo.gov/index?s=opportunity&mode=form&id=056306ed6f1b7ef2 f79215516c4b8dfe&tab=core&_cview=1 [accessed Mar. 8, 2011]. HHS. 2009b. National Health Security Strategy of the United States of America. U.S. Department of Health and Human Services. December 2009 [online]. Available: http://www.phe.gov/ Preparedness/planning/authority/nhss/strategy/Documents/nhss-final.pdf [accessed Mar. 9, 2011]. HHS. 2010a. Biennial Implementation Plan for the National Health Security Strategy of the United States of America. Draft Report, July 19, 2010 [online]. Available: http://www.phe. gov/Preparedness/planning/authority/nhss/comments/Documents/nhssbip-draft-100719.pdf [accessed Mar. 8, 2011]. HHS. 2010b. Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. U.S. Department of Health and Human Services, Assistant Secretary for Preparedness and Response. August 2010 [online]. Avail - able: https://www.medicalcountermeasures.gov/documents/MCMReviewFinalcover-508.pdf [accessed Mar. 8, 2011]. HHS. 2011. Centers for Innovation in Advanced Development and Manufacturing. Request for Proposal, Solicitation No. 11-100-SOL-00011. U.S. Department of Health and Human Ser- vices. FedBiz Opps [online]. Available: https://www.fbo.gov/index?s=opportunity&mode= form&id=d642fcb0614b1558e9c8482f57e327d0&tab=core&_cview=1 [accessed Jun. 6, 2011]. Hornick, R.B., A.T. Dawkins, H.T. Eigelsbach, and J.J. Tulis. 1966. Oral tularemia vaccine in man. Pp. 11-14 in Antimicrobial Agents and Chemotherapy, G.L. Hobby, ed. Bethesda, MD: American Society for Microbiology. Hough, D.E. 2010. TMT Overview. Presentation at the Transformational Medical Technologies Initiative (TMTI) Partnership Symposium, May 3, 2010, Lansdowne, VA [online]. Available: http://tmt-cbdefense.org/calendar/eventfiles/TMTI%20Program%20Overview.pdf [ac - cessed Mar. 10, 2011]. IOM (Institute of Medicine). 2002. Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military. Washington, DC: National Academies Press. IOM. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DOD Program to Develop Medical Countermeasures. Washington, DC: National Academies Press. IOM. 2009. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press. IOM. 2010. Public Health Emergency Countermeasures Enterprise, Innovative Strategies to En - hance Products from Discovery to Approval, Feb. 23-24, 2010, Washington, DC: National Academies Press.

OCR for page 139
144 PROTECTING THE FRONTLINE IN BIODEFENSE RESEARCH Jahrling, P., C. Rodak, M. Bray, and R.T. Davey. 2009. Triage and management of accidental labora - tory exposures to biosafety level-3 and -4 agents. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 7(2):135-143. Jochim, M.M., T.L. Barber, and A.J. Luedke. 1973. Venezuelan equine encephalomyelitis: Antibody response in vaccinated horses and resistance to infection with virulent virus. Journal of the American Veterinary Medical Association 162(4):280-283. Joint Chiefs. 2010. Joint Biological Warfare Defense Capabilities, Chairman of the Joint Chiefs of Staff Instruction. CJCSI 3112.01A, Feb. 9, 2010 [online]. Available: http://www.dtic.mil/ cjcs_directives/cdata/unlimit/3112_01.pdf [accessed Mar. 9, 2011]. JPEO-CBD (Joint Program Executive Office for Chemical and Biological Defense). 2011. Joint Vaccine Acquisition Program (JVAP). Joint Program Executive Office for Chemical and Bio - logical Defense [online]. Available: http://www.jpeocbd.osd.mil/packs/Default.aspx?pg=1208 [accessed Mar. 10, 2011]. Kaiser, J. 2007. Pathogen Work at Texas A&M Suspended. Science Now, July 2, 2007 [online]. Avail - able: http://news.sciencemag.org/sciencenow/2007/07/02-01.html [accessed Mar. 9, 2011]. Kimman, T.G., E. Smit, and M.R. Klein. 2008. Evidence-based biosafety: A review of the principles and effectiveness of microbiological containment measures. Clinical Microbiology Reviews 21(3):403-425. Kisskalt, K. 1915. Laboratory infections with typhoid bacilli. Zeitschrift fuer Hygiene und Infek - tionskrankheiten 80:145-162. Leifer, E., D.J. Gocke, and H. Bourne. 1970. Report of laboratory-acquired infection treated with plasma from a person recently recovered from the disease. American Journal of Tropical Medicine and Hygiene 19:677-679. Maiztegui, J.I., K.T. McKee, Jr., J.G. Barrera, L.H. Harrison, P.H. Gibbs, M.R. Feuillade, D.A. Enria, A.M. Briggiler, S.C. Levis, A.M. Ambrosio, N.A. Halsey, and C.J. Peters. 1998. Protective ef - ficacy of a live attenuated vaccine against Argentine hemorrhagic fever. Journal of Infectious Diseases 177(2):277-283. McClain, D.J., P.R. Pittman, H.H. Ramsburg, G.O. Nelson, C.A. Rossi, J.A. Mangiafico, A.L. Schmaljohn, F.J. Malinoski. 1998. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. Journal of Infectious Diseases 177(3):634-741. Meyer, K.F., and B. Eddie. 1941. Laboratory infections due to Brucella. Journal of Infectious Dis- eases 68(1):24-32. NBSB (National Biodefense Science Board). 2010a. Optimizing Industrial Involvement in Medical Countermeasure Development. National Biodefense Science Board, February 2010 [on- line]. Available: http://www.phe.gov/Preparedness/legal/boards/nbsb/meetings/Documents/ nbsbrpt-2010.pdf [accessed Mar. 9, 2011]. NBSB. 2010b. Where Are the Countermeasures? Protecting America’s Health from CBRN Threats. National Biodefense Science Board, March 2010 [online]. Available: http://www.phe.gov/ Preparedness/legal/boards/nbsb/meetings/Documents/nbsb-mcmreport.pdf [accessed Mar. 9, 2011]. Newmark, J. 2009. The Integrated National Biodefense Portfolio Initiative “One-Portfolio, JPEO CBD. Presented at the 2009 DOD Chemical Biological Defense Advance Planning Briefing for Industry (APBI), May 7, 2009 [online]. Available: http://www.jpeocbd.osd.mil/packs/Default. aspx?pg=851 [accessed Jan. 5, 2011]. NIAID (National Institute of Allergy and Infectious Diseases). 2007. NIAID Strategic Plan for Biodefense (2007 Update). U.S. Department of Health and Human Services, National In - stitutes of Health, National Institute of Allergy and Infectious Diseases [online]. Available: http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Documents/biosp2007.pdf [accessed Mar. 9, 2011].

OCR for page 139
145 REFERENCES NIAID. 2009. NIAID Category A, B, and C Priority Pathogens [online]. Available: http://www. niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/Pages/CatA.aspx [accessed Mar. 10, 2011]. NIAID. 2010. Regional Centers of Exellence for Biodefense and Emerging Infectious Diseases (RCEs): Overview [online]. Available: http://www.niaid.nih.gov/labsandresources/resources/ rce/pages/introduction.aspx [accessed Mar. 14, 2011]. NIAID. 2011. Resources for Researchers: Current National Biocontainment Laboratories (NBL) and Regional Biocontainment Laboratories (RBL) [online]. Available: http://www.niaid. nih.gov/LabsAndResources/resources/dmid/NBL_RBL/Pages/site.aspx [accessed Mar. 14, 2011]. Niklasson, B., J.M. Meegan, and E. Bengtsson. 1979. Antibodies to Rift Valley fever virus in Swedish U.N. soldiers in Egypt and the Sinai. Scandinavian Journal of Infectious Diseases 11(4):313-314. NIOSH (National Institute for Occupational Safety and Health). 1999. NIOSH Alert: Preventing Needlestick Injuries in Health Care Settings. Publication No. 2000-108. U.S. Department of Health and Human Services, Public Health Service, Centers for Diseases Control and Preven - tion, National Institute for Occupational Safety and Health. November 1999 [online]. Avail - able: http://www.cdc.gov/niosh/docs/2000-108/pdfs/2000-108.pdf [accessed Mar. 9, 2011]. NRC (National Research Council). 2009. Responsible Research with Biological Select Agents and Toxins. Washington, DC: National Academies Press. NRC. 2010. Evaluation of the Health and Safety Risks of the New USAMRIID High Containment Facilities at Fort Detrick, MD. Washington, DC: National Academies Press. NSC (National Security Council). 2009. National Strategy for Countering Biological Threats. National Security Council, The White House. November 2009 [online]. Available: http:// www.whitehouse.gov/sites/default/files/National_Strategy_for_Countering_BioThreats.pdf [accessed Mar. 9, 2011]. Olsen, G.H., M.J. Turell, and B.B. Pagac. 1997. Efficacy of eastern equine encephalitis immunization in whooping cranes. Journal of Wildlife Diseases 33(2):312-315. One Health. 2010. One Health Initiative [online]. Available: http://www.onehealthinitiative.com/ [accessed Mar. 15, 2011]. PATH. 2007. SA 14-14-2 Japanese Encephalitis (JE) Vaccine. April 2007 [online]. Available: http:// www.path.org/vaccineresources/files/SA14142_fact_sheet_15Feb08.pdf [accessed Mar. 14, 2011]. Paweska, J., L. Blumberg, J. Weyer, A. Kemp, P. Leman, B. Archer, D. Nkosi, and R. Swanepoel. 2008. Rift Valley fever outbreak in South Africa. Communicable Diseases Surveillance Bulletin (South Africa) 6(2):1-2. Pike, R.M. 1976. Laboratory-associated infections: Summary and analysis of 3921 cases. Health Laboratory Science 13(2):105-114. Pike, R.M. 1978. Past and present hazards of working with infectious agents. Archives of Pathology and Laboratory Medicine 102(7):333-336. Pike, R.M. 1979. Laboratory-associated infections: Incidence, fatalities, causes, and prevention. Annual Review of Microbiology 33:41-66. Pittman, P.R., R.S. Makuch, J.A. Mangiafico, T.L. Cannon, P.H. Gibbs, and C.J. Peters. 1996. Long term detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14(4):337-343. Pittman, P.R., K.M. Coonan, P.H. Gibbs, H.M. Scott, T.L. Cannon, and K.T. McKee, Jr. 2004. Long-term health effects of repeated exposure to multiple vaccines. Vaccine 23(4):525-536. Pittman, P.R., S.F. Leitman, J.G. Oro, S.L. Norris, N.M. Marano, M.V. Ranadive, B.S. Sink, and K.T. McKee, Jr. 2005a. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clinical and Diagnostic Laboratory Immunology 12(6):713-721.

OCR for page 139
146 PROTECTING THE FRONTLINE IN BIODEFENSE RESEARCH Pittman, P.R., S.L. Norris, K.M. Coonan, and K.T. McKee, Jr. 2005b. An assessment of health sta - tus among medical research volunteers who served in the Project Whitecoat program at Fort Detrick, Maryland. Military Medicine 170(3):183-187. Pouch Downes, F. 2010. Public Health Laboratory Vaccination Needs, Michigan Department of Community Health. Presentation at the Third Meeting on Special Immunizations Program, May 18, 2010, Washington, DC. Powers, A.M., and C.H. Logue. 2007. Changing patterns of Chikungunya virus: Re-emergence of a zoonotic arbovirus. Journal of General Virology 88(9):2363-2377. Riesman, D. 1898. Two cases of diphtheria, one from a laboratory infection, and one in an infant eleven days old. Philadelphia Medical Journal 1(10):422-424. Ruben, B., J.D. Band, P. Wong, and J. Colville. 1991. Person-to-person transmission of Brucella melitensis. The Lancet 337(8732):14-15. Rusnak, J.M., M.G. Kortepeter, J. Aldis, and E. Boudreau. 2004a. Experience in the medical manage- ment of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Journal of Occupational and Environmental Medicine 46(8):801-811. Rusnak, J.M., M.G. Kortepeter, R.J. Hawley, A.O. Anderson, E. Boudreau, and E. Eitzen. 2004b. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 2(4):281-293. Rusnak, J.M., M.G. Kortepeter, R.J. Hawley, E. Boudreau, J. Aldis, and P.R. Pittman. 2004c. Man - agement guidelines for laboratory exposures to agents of bioterrorism. Journal of Occupational and Environmental Medicine 46(8):791-800. Rusnak, J.M., P. Gibbs, E. Boudreau, D.P. Clizbe, and P. Pittman. 2011. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine. 2011 29(17):3222-3229. sanofi-pasteur. 2010. Company website: Origin [online]. Available: http://www.avpi.org/sanofi- pasteur2/ImageServlet?imageCode=27494&siteCode=SP_CORP [accessed Mar. 9, 2011]. Sawyer, J., A. Bennett, V. Haines, E. Elton, K. Crago, and S. Speight. 2007. The effect of micro - biological containment systems on dexterity. Journal of Occupational and Environmental Hygiene 493:166-173. Sawyer, W.A. 1932. Vaccination against yellow fever with immune serum and virus fixed for mice. Journal of Experimental Medicine 55(6):945-969. Simpson, A. 2010. An international perspective on immunizing laboratory researchers—UK Posi - tion. Presentation at the Second Meeting of the Committee on Special Immunizations Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents, May 18, 2010. Washington, DC. Sjöstedt, A. Laboratory of Molecular Infection Sweden (MIMS). E-mail to Alan Cross. Mar. 23, 2011. Top, F.H. Jr., J.J. Dingerdissen, W.H. Habig, G.V. Quinnan, Jr., and R.L. Wells. 2000. DoD Acquisi - tion of Vaccine Production: Report to the Secretary of Defense by the Independent Panel of Experts, Nov. 29, 2000. (Appendix D in DOD 2001)[online]. Available: http://www.defense. gov/pubs/reportonbiologicalwarfaredefensevaccineRDPrgras-July2001.pdf [accessed Mar. 10, 2011]. U.S. Department of the Army. 1990. Use of Volunteers as Subjects of Research. Army Regulation 70-25. Headquarters, U.S. Department of the Army, Washington, DC. Jan. 25, 1990 [online]. Available: http://armypubs.army.mil/epubs/pdf/R70_25.PDF [accessed Mar. 14, 2011]. U.S. Department of the Army. 1997. Medical Aspects of Chemical and Biological Warfare, F.R. Sidell, E.T. Takafuji, and D.R. Franz, eds. Textbooks of Military Medicine. Office of the Surgeon General, Boden Institute, Walter Reed Army Medical Center, Washington, DC [on - line]. Available: http://www.bordeninstitute.army.mil/published_volumes/chemBio/fm.pdf [accessed Mar. 10, 2011].

OCR for page 139
147 REFERENCES U.S. Department of the Army. 2007. Medical Aspects of Biological Warfare, Z.F. Dembek, ed. Textbooks of Military Medicine. Office of the Surgeon General, U.S. Army Medical Depart - ment Center and School, Boden Institute, Washington, DC [online]. Available: http://www. bordeninstitute.army.mil/published_volumes/biological_warfare/biological.html [accessed Mar. 10, 2011]. U.S. Department of the Army. 2010. Advanced Development and Manufacturing of Biologics- Based Chemical, Biological, Radiological, and Nuclear Defense Medical Countermeasures. Request for Information. Solicitation No.W911QY11XMCMI, U.S. Department of the Army. FedBizOpps [online]. Available: https://www.fbo.gov/index?s=opportunity&mode= form&id=6ad751b397cb963fb32f7d65d061ffdb&tab=core&_cview=0 [accessed Mar. 8, 2011]. USAMRIID (U.S. Army Medical Research Institute of Infectious Disease). 1995. Boards, Commis - sions and Committees. Regulation 15-1. June 30, 1995. USAMRIID. 2004. Risk Assessment and Special Immunizations Program Participation Request. Standard Operating Procedure SOP MD-06-06. September 10, 2004. USAMRIID. 2009. USAMRIID Special Immunizations Program (SIP) Clinic Capabilities. Decem - ber 15, 2009. Victoria, J.G., C. Wang, M.S. Jones, C. Jaing, K. McLoughlin, S. Gardner, and E.L. Delwart. 2010. Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventi - tious virus. Journal of Virology 84(12):6033-6040. Wedum, A.G. 1996. The Detrick experience as a guide to the probable efficacy of P4 microbio - logical containment facilities for studies on microbial recombinant DNA molecules. Applied Biosafety 1(1):7-25. Wedum, A.G., W.E. Barkley, and A. Hellman. 1972. Handling of infectious agents. Journal of the American Veterinary Medical Association 161(11):1557-1567. White House. 2007. Homeland Security Presidential Directive 18 (HSPD-18). Medical Counter- measures against Weapons of Mass Destruction. January 31, 2007. Available: http://www.dhs. gov/xabout/laws/gc_1219175362551.shtm [accessed Jun. 8, 2011]. White House. 2010. National Security Strategy. May 2010 [online]. Available: http://www.white - house.gov/sites/default/files/rss_viewer/national_security_strategy.pdf [accessed Mar. 9, 2011]. Widmer, J. 2000. The Spirit of Swiftwater: 100 Years at the Pocono Labs. Scranton, PA: University of Scranton Press. WRAIR (Walter Reed Army Institute of Research). 2010. Pilot Bioproduction Facility: Frequently Asked Questions. U.S. Army Medical Research and Materiel Command, Walter Reed Army Institute of Research [online]. Available: http://wrair-www.army.mil/Pilot_Bioproduction_ Facility/Welcome/ [accessed Mar. 9, 2011].

OCR for page 139